Anavex Life Sciences Corp

NASDAQ AVXL

Data sourced from

and

Download Data

Anavex Life Sciences Corp Cash Per Share 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: -12.41%

Anavex Life Sciences Corp Cash Per Share 1 year YoY Change (%) is -12.41% for the Trailing 12 Months (TTM) ending March 31, 2024, a -98.82% change year over year. The cash per share represents the amount of cash available to each outstanding share of common stock. It is calculated by dividing the total cash by the weighted average number of shares outstanding. This metric provides insight into the cash position of the company on a per-share basis and can be used to evaluate the company's liquidity and ability to distribute cash to shareholders. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Anavex Life Sciences Corp Cash Per Share for the Trailing 12 Months (TTM) ending March 31, 2023 was 1.93, a -6.24% change year over year.
Anavex Life Sciences Corp Cash Per Share for the Trailing 12 Months (TTM) ending March 31, 2022 was 2.06, a 197.81% change year over year.
Anavex Life Sciences Corp Cash Per Share for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.69, a 54.47% change year over year.
Anavex Life Sciences Corp Cash Per Share for the Trailing 12 Months (TTM) ending March 31, 2020 was 0.45, a -7.08% change year over year.

NASDAQ: AVXL

Anavex Life Sciences Corp

CEO	Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
IPO Date	Aug. 2, 2006
Location	United States
Headquarters	630 5th Avenue, New York, NY, United States, 10111
Employees	40
Sector	Healthcare
Industry	Biotechnology

Description

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Key trends